Amgen (AMGN) said Saturday that its cholesterol-lowering drug Repatha reduced the risk of first major cardiovascular events by 31% in high-risk diabetes patients without known significant atherosclerosis.

The company said that the findings came from a subgroup analysis of 3,655 patients in the phase 3 VESALIUS-CV trial followed for a median of 4.8 years.

Repatha was added to statins or other LDL-cholesterol-lowering therapies, Amgen said. The drug reduced the risk of coronary heart disease death, heart attack or ischemic stroke versus placebo, it added.

It also reduced a broader composite endpoint that included ischemia-driven revascularization by 31%, according to Amgen.